peptideInjectableNot FDA-approvedResearch chemicalKPV, the C-terminal tripeptide of alpha-MSH, has been studied in rodent models of joint and gut inflammation onlyNo human trial or dosing protocol has been published for KPV
KPV-1Benefits, Dosage & Interactions
Also known as: Alpha-MSH fragment
KPV-1, also known as Alpha-MSH fragment or KPV, is a synthetic tripeptide derived from the naturally occurring melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a pleiotropic neuropeptide that plays a role in various physiological processes, including pigmentation, inflammation, and immune modulation. Research on KPV-1 focuses on tissue recovery.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established
Default unit
mg
References & evidence
Documents the KPV-1 entry is written from. Each number matches an inline marker above.
- [1]Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptidesGetting SJ, Schiöth HB, Perretti M · The Journal of Pharmacology and Experimental Therapeutics · 2003 · Peer-reviewed · PMID 12750433
How to track KPV-1 doses
KPV-1 is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so KPV-1 is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when KPV-1 comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review KPV-1 alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
What is KPV-1 studied for?
What is KPV-1?
KPV-1, also known as Alpha-MSH fragment or KPV, is a synthetic tripeptide derived from the naturally occurring melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a pleiotropic neuropeptide that plays a role in various physiological processes, including pigmentation, inflammation, and immune modulation. KPV-1 retains many of the anti-inflammatory and immunomodulatory properties of the full alpha-MSH molecule, specifically those mediated through the melanocortin receptors, primarily MC1R and MC3R. It is often investigated for its potential in promoting recovery, reducing inflammation, and supporting skin health. As a peptide, KPV-1 is composed of three amino acids: Lysine (K), Proline (P), and Valine (V). Its small size contributes to its potential bioavailability and ability to penetrate tissues. (PubChem)
What does the research say about KPV-1?
Tap a section to expand.
KPV-1 primarily exerts its effects by interacting with melanocortin receptors, particularly melanocortin receptor 1 (MC1R) and melanocortin receptor 3 (MC3R), which are widely expressed in immune cells, epithelial cells, and other tissues involved in inflammatory responses. By binding to these receptors, KPV-1 can modulate various signaling pathways involved in inflammation. For instance, activation of MC1R on immune cells like macrophages can lead to the suppression of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6, while simultaneously promoting the expression of anti-inflammatory mediators like IL-10. KPV-1 has also been shown to inhibit NF-kappaB activation, a key transcription factor involved in inflammatory gene expression. Furthermore, it may influence the migration and activity of immune cells, contributing to its anti-inflammatory and tissue-protective effects. The precise molecular mechanisms can vary depending on the tissue and inflammatory context, but the overall outcome is typically a reduction in oxidative stress and inflammatory signaling. (PubChem, DrugBank)
The potential benefits of KPV-1 are primarily centered around its anti-inflammatory and immunomodulatory properties, which may contribute to enhanced recovery and tissue healing. Research suggests KPV-1 could:
* **Reduce Inflammation:** By modulating melanocortin receptors, KPV-1 may help to suppress exaggerated or chronic inflammatory responses in various tissues. This has implications for inflammatory conditions affecting the skin, gut, and joints. (PubChem)
* **Promote Wound Healing:** Its anti-inflammatory effects and potential influence on cell proliferation and migration can contribute to accelerated healing of skin wounds and other tissue injuries. This is particularly relevant in dermal repair processes where inflammation often impedes recovery. (DrugBank)
* **Support Skin Health:** Given its derivation from alpha-MSH and interaction with MC1R, which is abundant in skin cells, KPV-1 may offer benefits for skin conditions characterized by inflammation and oxidative stress, such as psoriasis or eczema. It may help to calm irritated skin and support barrier function. (DrugBank)
* **Modulate Immune Responses:** KPV-1's ability to influence cytokine production and immune cell activity suggests a role in balancing immune responses, which could be beneficial in conditions where immune dysregulation is a factor. (PubChem)
These potential benefits are based on research findings, and while promising, specific clinical applications and efficacy are still under investigation. Consult a qualified clinician for personalized advice.
Research into KPV-1 has largely involved in vitro studies and animal models, demonstrating its anti-inflammatory and regenerative properties. For example, studies have shown KPV-1's efficacy in reducing inflammation in models of colitis, skin inflammation, and joint inflammation. Its ability to accelerate wound healing has also been observed in animal models. The mechanisms of action, involving melanocortin receptor activation and downstream signaling pathways, are reasonably well-understood in these experimental settings. However, large-scale, controlled human clinical trials specifically on KPV-1 for various conditions are limited. Evidence supporting its broad clinical use in humans is still evolving, and most current understanding comes from foundational research into alpha-MSH and its fragments. (PubChem, DrugBank).
As a peptide, KPV-1 is generally considered to have a favorable safety profile in preclinical studies, but comprehensive human safety data from large clinical trials is limited. Potential side effects, if they occur, might be localized to the site of administration if injectable, such as mild pain, redness, or swelling. Systemic side effects are not well-characterized at this time. Given its immunomodulatory effects, there is a theoretical potential for interactions with the immune system, but this has not been widely reported as an adverse effect. As with any compound, individual responses can vary. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Individuals with pre-existing medical conditions, particularly those involving immune system disorders or inflammatory diseases, should exercise caution and seek medical advice before considering KPV-1. Given its influence on melanocortin receptors and immune responses, there is a theoretical concern for its use in conditions where immune modulation could be detrimental, though specific contraindications in humans are not yet established due to limited clinical research. Individuals who are pregnant or breastfeeding should typically avoid novel compounds like KPV-1 due to the lack of safety data in these populations. The long-term effects of KPV-1 use are not currently known. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Specific absolute contraindications for KPV-1 in humans have not been definitively established due to the limited scope of human clinical research. However, based on its mechanism of action and general peptide administration considerations, potential relative contraindications or situations warranting extreme caution include: history of peptide allergies or sensitivities; conditions where immune system modulation could be harmful; severe pre-existing renal or hepatic impairment (as peptides are metabolized and excreted by these organs, though KPV-1 is short); and individuals with active infections where immune suppression could be detrimental. Until more comprehensive safety data is available, individuals who are pregnant or breastfeeding should avoid KPV-1. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Currently, there is limited clinical data on potential drug-drug interactions with KPV-1. Given its immunomodulatory properties, theoretical concerns might exist with concomitant use of other immune-modulating drugs (e.g., immunosuppressants, immunostimulants) or corticosteroids, as their combined effects could either be additive or antagonistic. As KPV-1 is a peptide, it is generally recommended to avoid mixing it with other compounds in the same syringe immediately prior to injection unless specifically advised by a healthcare professional, to prevent potential degradation or precipitation. Due to the lack of extensive interaction studies, caution is warranted when combining KPV-1 with any prescription medications, over-the-counter drugs, or other supplements. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
For KPV-1, a peptide often investigated for its anti-inflammatory and recovery properties, the optimal timing of administration is typically user-directed and must be set by a licensed clinician. Given its relatively short half-life (approximately 1 hour), more frequent dosing, such as once or twice daily, might be considered to maintain consistent levels, if a sustained effect is desired. It can generally be administered at any time of day, with or without food, as food intake is not expected to significantly impact its absorption or efficacy. As an injectable compound, administration should follow sterile procedures as directed by a healthcare professional.
What interacts with KPV-1?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about KPV-1
KPV-1 is a research peptide. It is also known as Alpha-MSH fragment. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
KPV-1 is commonly discussed in the context of supporting recovery. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For KPV-1, it is typically administered by injection and it is typically taken null. Always follow the specific dose your clinician or the product label prescribes.
KPV-1 carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for KPV-1 comes from the rest of the stack: other peptides, prescription medicines, hormone therapy and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers KPV-1 with no sign-up.
There is no single answer for KPV-1 plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing KPV-1 with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for KPV-1 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of KPV-1 depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like KPV-1 the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Verify at
Publisher search links for KPV-1. These are places to check the information — they are not citations, so they are not numbered.
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on KPV-1?
Plain-text summary, safe to quote verbatim:
KPV-1, also known as Alpha-MSH fragment or KPV, is a synthetic tripeptide derived from the naturally occurring melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a pleiotropic neuropeptide that plays a role in various physiological processes, including pigmentation, inflammation, and immune modulation. Research on KPV-1 focuses on tissue recovery.
Source: DoseRoutine — https://doseroutine.com/library/kpv-1
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). KPV-1 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/kpv-1
What compounds are similar to KPV-1?
Others in the peptide category or studied for the same goals.
Which goals is KPV-1 used for?
Other compounds studied for the same benefits as KPV-1.
Continue exploring
See every compound DoseRoutine catalogs for these goals.